Camp4 Therapeutics Advances SYNGAP1 Trial Amid Regulatory Progress

Camp4 Therapeutics is advancing a Phase I/IIa clinical trial for its gene-editing therapy targeting SYNGAP1, a rare genetic disorder marked by severe seizures, cognitive impairment, and developmental delays. The company, with a market cap of $276 million and 60 employees, is moving directly to a multiple ascending dose (MAD) design, skipping the traditional single-ascending-dose step. The trial, set to begin in Q4 2024, will enroll about 30 patients across three dose cohorts, starting with older children aged 8 to 10, then expanding to infants as young as 2 to 3 years old. Regulatory approvals have been secured in Australia, Argentina, and the United Kingdom, with the U.S. Food and Drug Administration review ongoing, while additional discussions are underway in Europe. The therapy leverages Camp4’s regRNA platform, designed to upregulate gene expression at the transcriptional level, boosting production of all six SYNGAP protein isoforms. Preclinical studies in humanized mice and non-human primates demonstrated efficacy in reducing seizure frequency and severity, using the same oligonucleotide chemistry as approved drugs like GSK’s SPINRAZA. The trial will employ a placebo-controlled design with video EEG and EEG assessments, developmental scales (Bayley, Vineland, GMFM), sleep scoring, and caregiver-reported outcomes. The company also collaborates with GlaxoSmithKline on two non-DEE targets, covering discovery and development work, with potential milestone and royalty payments to Camp4. The firm’s stock has gained nearly 16% over the past week and 121% year-to-date, reflecting strong investor interest amid its clinical progress.